The development of nanobodies for therapeutic applications.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current opinion in investigational drugs

• Publication date

  2009-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 19876789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function

  2009cited by this paper
• Isolation and Functional Characterization of Single Domain Antibody Modulators of Caspase-3 and Apoptosis

  2009cited by this paper
• General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold*

  2009cited by this paper
• Cell selection and characterization of a novel human endothelial cell specific nanobody.

  2009cited by this paper
• Head‐to‐tail fusions of camelid antibodies can be expressed in planta and bind in rumen fluid

  2009cited by this paper
• Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation.

  2009cited by this paper
• Passive immunization with llama single-domain antibody fragments reduces foot-and-mouth disease transmission between pigs.

  2009cited by this paper
• Conditional Inactivation of HIF-1 Using Intrabodies

  2008cited by this paper
• Production and Characterization of a High-Affinity Nanobody Against Human Endoglin

  2008cited by this paper
• SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression

  2008cited by this paper
• Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens.

  2008cited by this paper
• Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120

  2008cited by this paper
• Llama-Derived Single-Chain Antibody Fragments Directed to Rotavirus VP6 Protein Possess Broad Neutralizing Activity In Vitro and Confer Protection against Diarrhea in Mice

  2008cited by this paper
• Passive immunization of pigs with bispecific llama single-domain antibody fragments against foot-and-mouth disease and porcine immunoglobulin.

  2008cited by this paper
• Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol.

  2008cited by this paper
• Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT

  2008cited by this paper
• Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils.

  2008cited by this paper
• VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'.

  2008cited by this paper
• Von Willebrand Factor in Cardiovascular Disease: Focus on Acute Coronary Syndromes

  2008cited by this paper
• Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  2008cited by this paper
• Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.

  2007cited by this paper
• A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1.

  2007cited by this paper
• Selection of Genetically Encoded Fluorescent Single Domain Antibodies Engineered for Efficient Expression in Escherichia coli*

  2007cited by this paper
• Properties, production, and applications of camelid single-domain antibody fragments

  2007cited by this paper
• Single domain antibodies from llama effectively and specifically block T cell ecto‐ADP‐ribosyltransferase ART2.2 in vivo

  2007cited by this paper
• The assembly of single domain antibodies into bispecific decavalent molecules.

  2007cited by this paper
• Production and characterization of anti‐(mucin MUC1) single‐domain antibody in tobacco (Nicotiana tabacum cultivar Xanthi)

  2007cited by this paper
• Improved anti-IgG and HSA affinity ligands: clinical application of VHH antibody technology.

  2007cited by this paper
• Studies of thermostability in Camelus bactrianus (Bactrian camel) single‐domain antibody specific for the mutant epidermal‐growth‐factor receptor expressed by Pichia

  2007cited by this paper
• Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease.

  2007cited by this paper
• Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs).

  2007cited by this paper
• Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.

  2007cited by this paper
• Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development.

  2007cited by this paper
• Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils

  2007cited by this paper
• Production of Chimeric Recombinant Single Domain Antibody—Green Fluorescent Fusion Protein in Chinese Hamster Ovary Cells

  2007cited by this paper
• Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies

  2007cited by this paper
• Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

  2006cited by this paper
• Llama Single-Chain Antibody That Blocks Lipopolysaccharide Binding and Signaling: Prospects for Therapeutic Applications

  2006cited by this paper
• Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries

  2006cited by this paper
• Targeting and tracing antigens in live cells with fluorescent nanobodies

  2006cited by this paper
• Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.

  2006cited by this paper
• Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment.

  2006cited by this paper
• Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation.

  2006cited by this paper
• Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea.

  2006cited by this paper
• Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy

  2006cited by this paper
• Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha

  2006cited by this paper
• Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris.

  2006cited by this paper
• Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor.

  2006cited by this paper
• Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library.

  2006cited by this paper
• Expression and Characterization of a Recombinant Single-Domain Monoclonal Antibody Against MUC1 Mucin in Tobacco Plants

  2006cited by this paper
• Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments.

  2006cited by this paper
• Design of a Peptibody Consisting of the Antimicrobial Peptide dhvar5 and a llama Variable Heavy‐chain Antibody Fragment

  2006cited by this paper
• A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B.

  2005cited by this paper
• Monoclonal antibody successes in the clinic

  2005cited by this paper
• Nanobodies as novel agents for cancer therapy

  2005cited by this paper
• The Production and Characterization of Novel Heavy-Chain Antibodies Against the Tandem Repeat Region of MUC1 Mucin

  2005cited by this paper
• Isolation of Llama Antibody Fragments for Prevention of Dandruff by Phage Display in Shampoo

  2005cited by this paper
• Llama Antibodies against a Lactococcal Protein Located at the Tip of the Phage Tail Prevent Phage Infection

  2005cited by this paper
• Production of bifunctional proteins by Aspergillus awamori: llama variable heavy chain antibody fragment (V(HH)) R9 coupled to Arthromyces ramosus peroxidase (ARP).

  2005cited by this paper
• The blood–brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells

  2005cited by this paper
• High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli.

  2005cited by this paper
• Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea.

  2005cited by this paper
• Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins.

  2005cited by this paper
• Production of a Novel Camel Single-Domain Antibody Specificfor the Type III Mutant EGFR

  2004cited by this paper
• Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents.

  2004cited by this paper
• Expression and production of llama variable heavy-chain antibody fragments (VHHs) by Aspergillus awamori

  2004cited by this paper
• Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in Camelus bactrianus

  2004cited by this paper
• Production of Novel Recombinant Single-Domain Antibodies against Tandem Repeat Region of MUC1 Mucin

  2004cited by this paper
• Efficient cancer therapy with a nanobody-based conjugate.

  2004cited by this paper
• Bactericidal Effects of a Fusion Protein of Llama Heavy-Chain Antibodies Coupled to Glucose Oxidase on Oral Bacteria

  2004cited by this paper
• Efficient Targeting of Conserved Cryptic Epitopes of Infectious Agents by Single Domain Antibodies

  2004cited by this paper
• Single Domain Antibodies Derived from Dromedary Lymph Node and Peripheral Blood Lymphocytes Sensing Conformational Variants of Prostate-specific Antigen*

  2004cited by this paper
• Intracellularly Expressed Single-Domain Antibody against p15 Matrix Protein Prevents the Production of Porcine Retroviruses

  2003cited by this paper
• Immunomodulation of enzyme function in plants by single-domain antibody fragments

  2003cited by this paper
• Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library.

  2003cited by this paper
• Immunized camel sera and derived immunoglobulin subclasses neutralizing Androctonus australis hector scorpion toxins.

  2003cited by this paper
• A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme

  2003cited by this paper
• Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy.

  2003cited by this paper
• Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains.

  2002cited by this paper
• Efficient tumor targeting by single‐domain antibody fragments of camels

  2002cited by this paper
• Single‐domain antibody fragments with high conformational stability

  2002cited by this paper
• Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties.

  2002cited by this paper
• Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology.

  2002cited by this paper
• Preventing phage lysis of Lactococcus lactis in cheese production using a neutralizing heavy-chain antibody fragment from llama.

  2002cited by this paper
• Thermal unfolding of a llama antibody fragment: a two-state reversible process.

  2001cited by this paper
• Functional heavy-chain antibodies in Camelidae.

  2001cited by this paper
• Lateral recognition of a dye hapten by a llama VHH domain.

  2001cited by this paper
• EGF mutant receptor vIII as a molecular target in cancer therapy.

  2001cited by this paper
• β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae

  2001cited by this paper
• Optimal Design Features of Camelized Human Single-domain Antibody Libraries*

  2001cited by this paper
• Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features.

  2000cited by this paper
• Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae.

  2000cited by this paper
• Camelid heavy-chain variable domains provide efficient combining sites to haptens.

  2000cited by this paper
• Camel heavy‐chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen‐binding repertoire

  2000cited by this paper
• Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama.

  2000cited by this paper
• Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies.

  1999cited by this paper
• A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

  1999cited by this paper
• A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops.

  1999cited by this paper
• Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies.

  1999cited by this paper
• The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation

  1999cited by this paper

• Advances in the Pharmaceutical Development of Antibody-Oligonucleotide Conjugates.

  2025cites this paper
• Nanobody-based Pannexin1 channel inhibitors increase survival after cardiac ischemia/reperfusion

  2025cites this paper
• De novo design of epitope-specific antibodies via a structure-driven computational workflow

  2025cites this paper
• Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa

  2025cites this paper
• The pharmacokinetics, bio-distribution and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in the Syrian golden hamster COVID-19 model

  2025cites this paper
• Minimalist Nanobody Architecture: A Double-edged Sword for Immunological Analysis

  2025cites this paper
• Towards a structural and functional analysis of the immunoglobulin-fold proteome.

  2024cites this paper
• A potent and selective anti-glutathione peroxidase 4 nanobody as a ferroptosis inducer

  2024cites this paper
• Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody.

  2024cites this paper
• Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant

  2024cites this paper
• 单域抗体标记技术及生物医学成像应用（特邀）

  2024cites this paper
• Characterization and humanization of VNARs targeting human serum albumin from the whitespotted bamboo shark (Chiloscyllium plagiosum).

  2024cites this paper
• Binding Efficacy of Heavy Chain Antibody Against Porcine Alpha Amylase Derived from Indian Camel (Camelus dromedarius)

  2024cites this paper
• Single-sequence protein structure prediction by integrating protein language models

  2024cites this paper
• Single-domain antibodies as therapeutics for solid tumor treatment

  2024cites this paper
• A SARS-CoV-2 Nanobody Displayed on the Surface of Human Ferritin with High Neutralization Activity

  2024cites this paper
• Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects.

  2023cites this paper
• Single domain Camelid antibody fragments for molecular imaging and therapy of cancer

  2023cites this paper
• Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies?

  2023cites this paper
• A cationic amphiphilic peptide chaperone rescues Aβ42 aggregation and cytotoxicity.

  2023cites this paper
• Structural Characterization of Nanobodies during Germline Maturation

  2023cites this paper
• The Search for Single-Domain Antibodies Interacting with the Receptor-Binding Domain of SARS-CoV-2 Surface Protein

  2023cites this paper
• RaptorX-Single: single-sequence protein structure prediction by integrating protein language models

  2023cites this paper
• Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies

  2022cites this paper
• Aptamers as promising nanotheranostic tools in the COVID‐19 pandemic era

  2022cites this paper
• Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective

  2022cites this paper
• Rapid-format recombinant antibody-based methods for the diagnosis of Clostridioides difficile infection: Recent advances and perspectives

  2022cites this paper
• Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life.

  2021cites this paper
• A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry

  2021cites this paper
• A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

  2020cites this paper
• CRISPR/Cas9-based Antibody Production in Plants

  2020cites this paper
• Nanobodies and their medical applications

  2020cites this paper
• Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.

  2020cites this paper
• New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter.

  2020cites this paper
• A VHH-Based Anti-MUC1 Chimeric Antigen Receptor for Specific Retargeting of Human Primary T Cells to MUC1-Positive Cancer Cells

  2020cites this paper
• Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications.

  2020cites this paper
• Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura

  2020cites this paper
• Discovery and characterization of single-domain antibodies for polymeric Ig receptor-mediated mucosal delivery of biologics

  2020cites this paper
• VHH characterization.Recombinant VHHs: Production, characterization and affinity.

  2020cites this paper
• Purine Release, Metabolism, and Signaling in the Inflammatory Response.

  2019cites this paper
• VHH characterization. Comparison of recombinant with chemically synthesized anti‐HER2 VHH

  2019cites this paper
• Jaký je současný stav a proč

  2019cites this paper
• Tinkering with targeting nucleotide signaling for control of intracellular Leishmania parasites.

  2019cites this paper
• Novel half‐life extended anti‐MIF nanobodies protect against endotoxic shock

  2018influential citation
• Single-domain antibody fragments derived from heavy-chain antibodies: a review

  2018cites this paper
• Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

  2018cites this paper
• JCB_201709115 1143..1154

  2018cites this paper
• A toolbox of anti–mouse and anti–rabbit IgG secondary nanobodies

  2018cites this paper
• Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence

  2018cites this paper
• Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks

  2018cites this paper
• The geroproTecTiVe effecTs of inhiBiTors suppressing aging-associaTeD signaling cascaDes in moDel organisms

  2017cites this paper
• baboon model of acquired thrombotic thrombocytopenic purpura Short title: ALX-0681 treatment of acquired TTP in baboons Authors

  2017cites this paper
• Nanobodies®† as inhaled biotherapeutics for lung diseases

  2017cites this paper
• Exploiting Nanobodies in the Detection and Quantification of Human Growth Hormone via Phage-Sandwich Enzyme-Linked Immunosorbent Assay

  2017cites this paper
• A toolbox of anti-mouse and rabbit IgG secondary nanobodies

  2017cites this paper
• Small molecule probes of protein aggregation

  2017cites this paper
• Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo

  2017cites this paper
• VHH AGAINST BACE1 INHIBITS BETA‐SECRETASE ACTIVITY IN VITRO AND IN VIVO

  2017cites this paper
• Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

  2017influential citation
• Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.

  2017cites this paper
• Recent Updates on Molecular Genetic Engineering Approaches and Applications of Human Therapeutic Proteins.

  2017cites this paper
• Novel Antibody-Targeted Liposomes for the Treatment of Solid Tumors

  2016cites this paper
• SINGLE DOMAIN ANTIBODIES AND BIOENGINEERING DRUGS ON THEIR BASIS: NEW OPPORTUNITIES FOR DIAGNOSTICS AND THERAPY

  2016cites this paper
• Nanobody-Based Interactomic Studies of Single Transcripts During mRNA Maturation

  2016cites this paper
• Mapping the dynamics and nanoscale organization of synaptic adhesion proteins using monomeric streptavidin

  2016cites this paper
• Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation

  2016cites this paper
• Nanobodies as therapeutics: big opportunities for small antibodies.

  2016cites this paper
• Phage display and Shiga toxin neutralizers.

  2016cites this paper
• Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®

  2015cites this paper
• The Role of Toll-Like Receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A New Promising Therapeutic Approach?

  2015cites this paper
• Camelid heavy chain only antibody fragment domain against β‐site of amyloid precursor protein cleaving enzyme 1 inhibits β‐secretase activity in vitro and in vivo

  2015cites this paper
• Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

  2015cites this paper
• Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages

  2015cites this paper
• Nanobodies and their Use in GPCR Drug Discovery.

  2015cites this paper
• Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena.

  2015influential citation
• Potent and Efficacious Inhibition of CXCR2 Signaling by Biparatopic Nanobodies Combining Two Distinct Modes of Action

  2015cites this paper
• The use of camel antibodies in development of EGFRvIII enzyme-linked immunosorbent assay

  2015cites this paper
• Selection of Nanobodies that Block the Enzymatic and Cytotoxic Activities of the Binary Clostridium Difficile Toxin CDT

  2015cites this paper
• Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer

  2015cites this paper
• A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting

  2015cites this paper
• A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.

  2014cites this paper
• Cytokines in inflammatory bowel disease

  2014cites this paper
• A novel platform for engineering blood‐brain barrier‐crossing bispecific biologics

  2014cites this paper
• Toll-like receptors in Alzheimer's disease: a therapeutic perspective.

  2014cites this paper
• Controlled release of therapeutic antibody formats.

  2014cites this paper
• Generation and characterization of nanobodies against rhGH expressed as sfGFP fusion protein.

  2014cites this paper
• Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction

  2014cites this paper
• The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes

  2014cites this paper
• LC-MS/MS quantification of next-generation biotherapeutics: a case study for an IgE binding Nanobody in cynomolgus monkey plasma.

  2014cites this paper
• Phage Display Selection of Antibody Fragments targeted to VEGFR-3 Dimerization Domain

  2014cites this paper
• O Bi technology IranianJournal of Expression and Purification of Brucella-Specific Nanobodies

  2014cites this paper
• Inhibition of CXCR2 signalling by biparatopic nanobodies Corresponding authors

  2014cites this paper
• The art of blocking ADP‐ribosyltransferases (ARTs): Nanobodies as experimental and therapeutic tools to block mammalian and toxin ARTs

  2013cites this paper
• Single‐Domain Antibodies and Their Utility

  2013influential citation
• Expression and Purification of Brucella-Specific Nanobodies

  2013cites this paper
• Anti‐c‐MET Nanobody® – a new potential drug in multiple myeloma treatment

  2013influential citation
• Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: A potential therapeutic use

  2013cites this paper
• IgA nephropathy: molecular mechanisms of the disease.

  2013cites this paper
• Platelet Biology and Receptor Pathways

  2013cites this paper
• Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target

  2013cites this paper